BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38750991)

  • 1. Efficacy and Safety of P2Y
    Casula M; Casu G; Talanas G; Spano A; Tantry U; Bilotta F; Micheluzzi V; Merella P; Porcheddu T; Gorog DA; Bonaca M; Jeong YH; Farkouh ME; Kubica J; Isgender M; Gurbel PA; Navarese EP
    Curr Probl Cardiol; 2024 Aug; 49(8):102635. PubMed ID: 38750991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
    Valgimigli M; Gragnano F; Branca M; Franzone A; da Costa BR; Baber U; Kimura T; Jang Y; Hahn JY; Zhao Q; Windecker S; Gibson CM; Watanabe H; Kim BK; Song YB; Zhu Y; Vranckx P; Mehta S; Ando K; Hong SJ; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Calabrò P; Jüni P; Mehran R;
    JAMA Cardiol; 2024 May; 9(5):437-448. PubMed ID: 38506796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
    Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
    Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
    Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
    Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2Y
    Jin Y; Huang H; Shu X; Chen S; Lu L; Gao X; Wu Z
    Thromb Res; 2021 Feb; 198():115-121. PubMed ID: 33316640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2Y
    Gragnano F; Mehran R; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Calabrò P; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Valgimigli M;
    J Am Coll Cardiol; 2023 Feb; 81(6):537-552. PubMed ID: 36754514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention.
    Malik AH; Yandrapalli S; Shetty SS; Aronow WS; Cooper HA; Panza JA
    Am J Cardiol; 2020 Jul; 127():25-29. PubMed ID: 32389351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
    Gelbenegger G; Schoergenhofer C; Jilma B; Gager GM; Dizdarevic AM; Mamas MA; Parapid B; Velagapudi P; Siller-Matula JM
    Clin Pharmacol Ther; 2021 Aug; 110(2):424-431. PubMed ID: 33668076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
    Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention.
    McClure JD; Ramsay JC; Berry C
    J Am Heart Assoc; 2020 Aug; 9(16):e017109. PubMed ID: 32779497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
    Wu XT; He RR; Liang SZ; Ye GY; Ding SB
    Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
    Valgimigli M; Gragnano F; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Jüni P; Mehran R
    BMJ; 2021 Jun; 373():n1332. PubMed ID: 34135011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Kuno T; Ueyama H; Takagi H; Bangalore S
    Am Heart J; 2020 Sep; 227():82-90. PubMed ID: 32693196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
    Wernly B; Rezar R; Gurbel P; Jung C
    J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
    De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
    BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials.
    Shoji S; Kuno T; Ueyama H; Takagi H; Briasoulis A; Kim HS; Koo BK; Kang J; Watanabe H; Kimura T; Kohsaka S
    J Cardiol; 2024 May; 83(5):338-347. PubMed ID: 37562542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
    Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
    Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abbreviated Dual Antiplatelet Therapy Followed by P2Y
    Kumar A; Shariff M; Doshi R; Vaz IP
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):355-361. PubMed ID: 31784888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.